A report at Nautilus says Eli Lilly and Novo Nordisk announced last week that their GLP-1 drugs are associated with a reduction in biological age. The data was presented at the 13th annual Aging Research and Drug Discovery conference, and it has not been peer reviewed.

The drugs are tirzepatide, made by Eli Lilly, and semaglutide, made by Novo Nordisk, both already familiar as weight-loss and diabetes treatments. "Biological age" here means age as measured by molecular clocks, which typically track epigenetic changes across a set of genes, including genes involved in metabolic pathways.

What the companies showed

According to the presentations, people taking the drugs had molecular ages two to three years younger than those who took only placebos. A separate clock tracking proteins related to the heart showed a four-year reduction.

That is a specific, quantified claim about aging, which is more than most of this field manages. It is also a claim made by the two companies that sell the drugs, at a conference, before anyone outside those companies has seen the analysis.

Why the caveats matter

The data came out of clinical trials run for the medications themselves, and Nautilus notes it has yet to be analyzed by a third party. Peer review has not happened either.

The trial populations are the other constraint. Participants were already overweight and diabetic rather than healthy adults, so whether a two-year shift in a molecular clock means anything for someone who is neither is an open question.

The longevity problem

GLP-1s are relatively new, and so are molecular clocks. Nautilus points out that any research showing significant longevity benefits will likely take time, which is the unglamorous reality of every lifespan claim ever made.

There is still a real case for interest here. Early studies cited in the piece report improved kidney function, cardiovascular effects and even reduced addiction behaviors, which suggests these drugs act across organ systems rather than on weight alone.

Bottom line

The side effects travel with the benefits, and muscle loss in particular could cause additional problems that cut against any aging story. As Nautilus puts it, settling this will take time and research conducted by people whose paychecks are not signed by drug companies.